Sarcoidosis reflects a multisystem granulomatous disease of unknown etiology that is characterized by
S
arcoidosis is described as a multisystem granulomatous disease of unknown etiology that is characterized by the formation of non-caseating granuloma in various organs（1,2） . The etiology of cardiac sarcoidosis still remains to be further elucidated, while environmental, occupational, and infectious causes are assumed to trigger an immunologic response in genetically predisposed individuals（2） . The prevalence of sarcoid manifestation is quite variable and contingent upon ethnicity, gender and regions（3） . For example, the prevalence is 10−40/100 000 persons in the United States and Europe, while there is an increased prevalence of sarcoidosis in African-American as compared to Caucasians with a ratio ranging from 10−17: 1（1） .
Interestingly, in the Scandinavian population the prevalence of sarcoidosis is markedly higher than in other whites with 50-60 per 100 000 individuals. In the japanese population the prevalence of sarcoid is reported to be 1.01 per 100 000 inhabitants and related to gender（prevalence of 0.73 in males and 1.28 in females） （4） . Gender has been appreciated to play a pivotal role in sarcoid manifestation as women are more frequently affected with a peak incidence below 40 years of age（5） . While systemic sarcoid disease most frequently manifests in the perihilar-mediastinal lymph nodes and in the lungs, the disease can affect also any other organ（6） . In one out of four patients with sarcoid disease, cardiac involvement is likely to ensue. Clinically, cardiac sarcoid disease is underdiagnosed but it is anticipated to be the predominant cause of death by sarcoidosis in Japan and in the United States（3,7） . Involvement of the septum is likely to cause conductance abnormalities most frequently a third-degree atrioventricular block（14-30%）in young and middle-aged adults（11,12） . Such middle-aged patients （＜55 years）with sarcoid induced third-degree atrioventricular block are at high risk to suffer cardiac death, heart failure, ventricular fibrillation, or ventricular tachycardia as previous investigations have shown （12） . Of note, ventricular tachycardia has been reported in up to 23% of cardiac sarcoid patient and it reflects the second most common clinical finding（13） . Unfortunately, sudden cardiac death may manifest in up to 40% as first clinical manifestation（14） . Apart from arrhythmic complications, the development of congestive heart failure is not seldom and it manifests in 73% of patients with lethal outcome. Congestive heart failure in cardiac sarcoidosis may be primarily related to extensive myocardial infiltration but also due to pulmonary arterial hypertension induced right heart failure, or valve insufficiency due to papillary muscle involvement.
Clinical manifestation
Generally, an involvement of the heart in sarcoid disease 
